Assay News and Research

RSS

Neonatal TSH screening insensitive for iodine insufficiency

Measuring levels of neonatal thyroid-stimulating hormone may not be sufficiently sensitive for inferring the extent of iodine deficiency in a given population, study results suggest.

5 Nov 2012

Weill Cornell researchers awarded Grand Challenges Explorations grants

Weill Cornell Medical College announced today that it is a Grand Challenges Explorations winner, an initiative funded by the Bill & Melinda Gates Foundation.

3 Nov 2012

Researchers develop new technique to predict enzymes known to accelerate diseases

Predicting how atherosclerosis, osteoporosis or cancer will progress or respond to drugs in individual patients is difficult.

3 Nov 2012

Link between ChemoFx Drug Response Marker results and RFS of cervical cancer patients

A new study reporting an association between ChemoFx Drug Response Marker results and recurrence free survival (RFS) of cervical cancer patients was presented at the 14th Biennial Meeting of the International Gynecologic Cancer Society (IGCS), held in Vancouver October 13-16, 2012.

2 Nov 2012

Fluidigm unveils four innovative devices to meet challenges associated with production genomics

Fluidigm Corporation today introduced four new integrated fluidic circuits (IFCs) designed to meet the challenges associated with production genomics.

2 Nov 2012

Biomarker discovery offers hope for lung cancer blood test

Blood levels of a variant form of the nuclear matrix protein Ciz1 are significantly higher in individuals with early- and late-stage lung cancer than in lung cancer-free individuals, researchers report.

31 Oct 2012

Luminex third quarter revenue increases 10% to $50.0 million

Luminex Corporation today announced financial results for the third quarter ended September 30, 2012.

From Luminex 30 Oct 2012

AOAC-PTM validates 3M Tecra Listeria Visual Immunoassay

3M Food Safety announced today that its 3M Tecra Listeria Visual Immunoassay (VIA) for Environmental Testing (#091201) has received validation from the AOAC Research Institute's Performance Tested Methods Program.

29 Oct 2012

Scientists develop new prototype ultra sensitive disease sensor

Scientists have developed a prototype ultra-sensitive sensor that would enable doctors to detect the early stages of diseases and viruses with the naked eye, according to research published today in the journal Nature Nanotechnology.

29 Oct 2012

FDA approves Hologic’s APTIMA HPV 16 18/45 Genotype Assay for use on TIGRIS system

Hologic, Inc., a leading developer, manufacturer and supplier of premium diagnostics, medical imaging systems and surgical products dedicated to serving the healthcare needs of women, today announced that the U.S. Food and Drug Administration (FDA) has approved the Company's APTIMA HPV 16 18/45 Genotype Assay for use on its TIGRIS instrument system.

From Hologic, Inc. 16 Oct 2012

Critical Diagnostics signs agreements with four new European distributors

Critical Diagnostics, a U.S.-based biomarker company focused on cardiovascular diseases, today announced that it has signed agreements with four new European distributors in Germany, Spain, France and Turkey.

15 Oct 2012

Novel method can determine how ready acute myeloid leukemia cells are to die

Researchers at Dana-Farber Cancer Institute have developed a novel method for determining how ready acute myeloid leukemia (AML) cells are to die, a discovery that may help cancer specialists to choose treatments option more effectively for their patients who have AML.

12 Oct 2012

Alverix receives FDA 510(k) clearance for new BD Veritor System kit

Alverix, Inc., a world leader in the design and manufacture of next-generation platforms for diagnostic Point-of-Care (POC) testing, today announced that BD Diagnostics, a segment of Becton Dickinson and Company, a leading global medical technology company, received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for nasopharyngeal wash, aspirate and swab in transport media specimens on the BD VeritorTM System for Rapid Detection of respiratory syncytial virus (RSV).

12 Oct 2012

Functional profiling using EVA/PCD doubles response rate and improves survival in NSCLC patients

Functional profiling using ex-vivo analysis of programmed cell death (EVA/PCD) doubles the response rate and improves time-to-progression and survival in patients with advanced lung cancer, according to a Phase II clinical trial conducted by investigators at Rational Therapeutics and the MemorialCare Todd Cancer Institute and published in the October issue of Anticancer Research.

8 Oct 2012

Top-line data from Pfizer’s Prevenar 13 Phase 3 trial on pneumococcal disease

Pfizer Inc. today announced top-line data assessing immunogenicity, tolerability and safety of Prevenar 13 (Pneumococcal polysaccharide conjugate vaccine [13-valent, absorbed]) in adults 18 to 49 years of age.

5 Oct 2012

Treatment with Lfcin4-14 reduces DNA damage in colon cancer cells exposed to UV light

Milk consumption has been linked to improved health, with decreased risks of diabetes, metabolic syndrome, and colon cancer. A group of scientists in Sweden found that lactoferricin4-14 (Lfcin4-14), a milk protein with known health effects, significantly reduces the growth rate of colon cancer cells over time by prolonging the period of the cell cycle before chromosomes are replicated. In a new study, investigators report that treatment with Lfcin4-14 reduced DNA damage in colon cancer cells exposed to ultraviolet (UV) light.

4 Oct 2012

PLOS ONE journal releases report on validation of Falcon Genomics' Cancer BioChip System

The online journal PLOS ONE released a scientific report on the validation of Falcon Genomics' Cancer BioChip System (CBCS) as a tool for identifying inhibitors of breast cancer.

29 Sep 2012

Eat fruit and veggies to prevent heart attack, women told

A diet that is high in antioxidants can reduce the risk for myocardial infarction in women, a study suggests.

26 Sep 2012

Flow cytometry isolates stem cells from brain tumors

A new video protocol in Journal of Visualized Experiments (JoVE) details an assay to identify brain tumor initiating stem cells from primary brain tumors. Through flow cytometry, scientists separate stem cells from the rest of the tumor, allowing quick and efficient analysis of target cells. This approach has been effectively used to identify similar stem cells in leukemia patients.